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Objective. To investigate the possible relationship between the presence of salivary stones and systemic diseases, medication,
smoking, and alcohol consumption.
Study Design. A retrospective, case control study. Medical records of patients with salivary stones and those of control patients
without salivary stones were retrospectively reviewed. Data regarding the affected salivary gland, the presence of systemic
disease, and the use of medication, tobacco, and alcohol were recorded. Statistical analysis was performed using the Fisher
Exact tests.
Results. Medical records of 208 patients with salivary stones and those of 208 control patients were reviewed. Of the patients
diagnosed with salivary stones, the submandibular gland was affected in 85.6% of the patients, the parotid gland in 9.6%, and
the sublingual gland in 2.4% of the patients. None of the recorded systemic diseases was more prevalent in patients with
salivary stones. Patients with salivary stones used significantly more antibiotics compared with the control group (P ¼ .037).
No significant differences were observed for other types of medication. There was no correlation between salivary stone
formation, smoking, and alcohol consumption.
Conclusions. The present study suggested that systemic diseases, medication, smoking, and alcohol consumption play no or
only a limited role in the onset of salivary stones. (Oral Surg Oral Med Oral Pathol Oral Radiol 2015;119:539-543)Salivary stones occur as one or more calciﬁed structures
within the salivary ductal system. The formation of
salivary stones, also known as sialoliths, can result in
partial or total obstruction of the ductal system leading
to recurrent swelling of the salivary gland, pain, and
acute or chronic infection. The annual incidence of
salivary stones is estimated between 1 per 15,000 and 1
per 30,000 individuals.1 Salivary stones occur most
often in patients over 40 years of age and rarely in
children.2 In studies published before 1990, a male
predominance is evident. However, more recent
studies have shown an almost equal distribution
between males and females.3-10 More than half of the
salivary stones have a diameter between 2.1 and 10
mm, and only 7.6% are larger than 15 mm in section.11
Salivary stones are more often located within the
ductal system of the submandibular gland (72%-95%)
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http://dx.doi.org/10.1016/j.oooo.2015.01.01028%). Salivary stones are seldom found in the sublin-
gual glands or accessory salivary glands.5,6,9-11 The
higher incidence of salivary stones in the ductal system
of the submandibular gland might be attributed to its
longer duct, salivary ﬂow against gravity, and a more
alkaline saliva with a higher calcium and mucin
content.9
The cause of salivary stone formation remains unclear.
However, there are two main theories that attempt to
explain the formation of salivary stones. The ﬁrst theory
postulates that a local inﬂammatory process leads to
calciﬁcation of a mucus plug. The second theory assumes
that microsialoliths, produced by autophagosomes in the
salivary gland, form a nidus for calcium precipitation.2
Salivary stones are mainly composed of inorganic ma-
terial, such as hydroxyapatite, carbonate apatite, whitlock-
ite, and brushite, with smaller amounts of organic material,
suchas collagen, glycoproteins, lipids, andcarbohydrates.11
Kidney stones mainly contain calcium oxalate, uric acid,
struvite, cystine, and small amounts of phosphate and
ammonium.12 The main components of gallstones are
cholesterol, bilirubin, bile acids, calcium apatite, and
small amounts of magnesium and struvite.13Statement of Clinical Relevance
The etiology of the development of a salivary stone
is still not clear. We found that systemic diseases,
medication, smoking, and alcohol consumption play
no or only a limited role in the onset of salivary
stones.
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concomitant with gallstones14 or kidney stones15 have
been described. Conﬂicting data were obtained when
this possible relationship was investigated in groups of
patients with salivary stones. Lustmann and co-
workers6 found an incidence of kidney stones of 10.7%
in a group of 56 patients with salivary stone formation.
This is higher than the incidence in the general
population and suggests a relationship between salivary
stone formation and nephrolithiasis. However, Zenk
et al.10 did not ﬁnd a higher prevalence of
nephrolithiasis (2%) and cholelithiasis (1.6%) in a
group of 635 patients with salivary stone formation
compared with the general population. Huoh et al.16
retrieved data from the medical records of patients
diagnosed with salivary stones at the University of
California. They also did not ﬁnd a higher prevalence
of cholelithiasis in patients with salivary stone
formation compared with the general population.
In the studies cited above,6,10,16 the incidence of
systemic disorders in patients with salivary stone for-
mation was compared with data on the prevalence of
diseases in the general population obtained from other
studies. To our knowledge, no case control studies have
investigated the potential association between systemic
disorders and the development of salivary stones.
Therefore, we performed a case control study to explore
the relationship between the onset of salivary stones
and the presence of systemic diseases, use of medica-
tion, and lifestyle factors.
MATERIALS AND METHODS
A retrospective case control study was conducted. The
study group consisted of patients with salivary stones
who had undergone surgical removal of sialoliths in the
VU University Medical Center Amsterdam, Catharina
Hospital in Eindhoven and Onze Lieve Vrouwe Gast-
huis in Amsterdam in The Netherlands from November
1, 2001, until December 31, 2013. All patients had
been referred to the hospitals because of symptomatic
salivary stones. A total of 208 medical reports of
patients with salivary stones were available for anal-
ysis. Each patient with a salivary stone was matched
with an age- and control-matched individual presenting
at the same departments of Oral and Maxillofacial
Surgery with medical problems other than a salivary
stone.
The medical records of both the study patients and the
matched control patients were systematically reviewed.
The following clinical data were retrieved and processed
anonymously into an Excel spreadsheet: the affected
salivary gland and the presence of hyperthyroidism,
diabetes, cardiovascular disease, hypertension, human
immunodeﬁciency virus (HIV), tuberculosis, choleli-
thiasis, nephrolithiasis, cirrhosis, hepatitis, Parkinsondisease, epilepsy, rheumatoid arthritis, Sjögren syn-
drome, gout, and malignancies. Data about medication
use were obtained and categorized according to the
Dutch national formulary (Pharmacotherapeutisch
Kompas).17 The records were also analyzed for in-
formation about current use of tobacco, alcohol, or
both. When data on smoking or use of alcohol were
available in the patients’ records, these data were
processed as yes/no.
Statistical analysis was performed using IBM SPSS
Statistics for Windows, version 21.0 (IBM Inc.,
Armonk, NY), using the Fisher Exact two-sided tests. P
values less than .05 were considered signiﬁcant.
RESULTS
A total of 208 patients with salivary stones, with 112
males (54%) and 96 females (46%) (male-to-female
ratio: 1.17:1) and a mean age of 46.8 years (range 8-87
years), were identiﬁed. A case control group consisting
of 208 patients, with 112 males and 96 females and a
mean age of 46.4 years (range 8-88 years), was created.
The submandibular gland was affected in 85.6% of the
patients, the parotid gland in 9.6%, and the sublingual
gland in 2.4%.
The prevalence of systemic diseases in both the patient
group and the control group is presented in Table I. No
relationship was found between salivary stone
formation and most systemic diseases. However, the
prevalence of cholelithiasis and Sjögren syndrome was
almost signiﬁcantly higher in the control group than in
patients with salivary stones (P ¼ .061).
There was a lack of data regarding smoking in 72%
of the patients with salivary stone formation and in 51%
of the control patients. In the available documents,
however, there was a trend toward statistical signiﬁ-
cance (P ¼ .097), with 49.2% smokers identiﬁed
among 59 patients with salivary stone formation and
34.9% smokers among 106 control patients. Data
regarding alcohol use were lacking in the records of
76% of the patients with salivary stone formation and
57% of the control patients. The available data did not
show a signiﬁcant difference in alcohol consumption
between the 50 individuals with salivary stone forma-
tion (50%) and the 90 individuals from the control
group (55.6%) (P ¼ .597).
DISCUSSION
Several studies have investigated the possible relation
between salivary stone formation and systemic diseases
or use of medication. Lustmann and co-workers6 found
an incidence of kidney stones of 10.7% in patients with
salivary stone formation, which was considerably
higher than the incidence in the general population.
In our case control study, the prevalence of
nephrolithiasis in the patient group did not differ from
Table I. Prevalence of systemic diseases in patients
with salivary stone formation and control patients (both
n ¼ 208)
Salivary
stone
formation Control
(Fisher
Exact test)
P value
Endocrine diseases
Hyperthyroidism 0 (0%) 1 (0.5%) 1.000
Diabetes 9 (4.3%) 6 (2.9%) .600
Cardiovascular diseases
Hypertension 21 (10.1%) 23 (11.1%) .874
Cardiovascular disease
(other than hypertension)
19 (9.1%) 19 (9.1%) 1.000
Infectious diseases
Human immunodeﬁciency
virus (HIV)
0 (0%) 0 (0%) d
Tuberculosis 1 (0.5%) 0 (0%) 1.000
Hepatitis 2 (1%) 2 (1%) 1.000
Internal diseases
Cholelithiasis 0 (0%) 5 (2.4%) .061
Nephrolithiasis 3 (1.4%) 3 (1.4%) 1.000
Cirrhosis 0 (0%) 1 (0.5%) 1.000
Neurologic diseases
Parkinson disease 0 (0%) 0 (0%) d
Epilepsy 2 (1%) 1 (0.5%) 1.000
Rheumatologic diseases
Rheumatoid arthritis 1 (0.5%) 4 (1.9%) .372
Sjögren syndrome 0 (0%) 5 (2.4%) .061
Gout 0 (0%) 0 (0%) d
Malignant diseases 8 (3.8%) 12 (5.8%) .493
Table II. Medication used by patients with salivary
stone formation and control patients (both n ¼ 208)
Salivary
stone
formation Control
(Fisher
Exact test)
P value
Cardiovascular medication 44 (21.5%) 40 (19.2%) .714
Diuretics 16 (7.7%) 14 (6.7%) .850
Antidiabetes agents 8 (3.8%) 9 (4.3%) 1.000
Stomach medication 21 (10.1%) 23 (11.1%) .874
Rheumatism medication 0 (0%) 2 (1%) .499
Analgesics 7 (3.4%) 13 (6.3%) .251
Anti-inﬂammatory drugs 18 (8.7%) 21 (10.1%) .737
Antiepileptics 3 (1.4%) 2 (1%) 1.000
Migraine medication 1 (0.5%) 3 (1.4%) .623
Respiratory medication 19 (9.1%) 16 (7.7%) .724
Antidepressants 6 (2.9%) 11 (5.3%) .322
Anxiolytics 4 (1.9%) 2 (1%) .685
Oral contraceptives 5 (2.4%) 5 (2.4%) 1.000
Thyroid medication 2 (1%) 4 (1.9%) .685
Bisphosphonates 2 (1%) 7 (3.4%) .175
Antihistamines 9 (4.3%) 9 (4.3%) 1.000
Antipsychotics 1 (0.5%) 3 (1.4%) .623
Benzodiazepines/hypnotics 2 (1%) 3 (1.4%) 1.000
Antibiotics 8 (3.8%) 1 (0.5%) .037
Dietary supplements 10 (4.8%) 14 (6.7%) .529
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similar to those in the studies of Zenk et al.10 and
Huoh et al.,16 who reported prevalence rates of
kidney stones comparable with those in the general
population. This suggests that the risk factors for
developing a salivary stone and a kidney stone are
not related. An Italian study reported high prevalence
rates of diabetes mellitus (25%) and hypertension
(20%) in patients with salivary stone formation.4
However, in a subsequent study, the prevalence rates
of hypertension and diabetes mellitus were
comparable with the prevalence rate in the general
population.10 In our case control study, we also
observed no differences in the prevalence rates of
hypertension and diabetes mellitus (see Table I).
Leung et al14 described a 49-year-old man with
multiple salivary stones and a medical history of mul-
tiple gallstones. We observed a nonsigniﬁcant higher
prevalence of cholelithiasis in the control group than in
the patients with salivary stone formation (see Table I).
In a previous study, the prevalence of cholelithiasis in a
group of 635 patients with salivary stone formation was
not higher than in the general population,10 which was
conﬁrmed by Huoh et al.16
It is hypothesized that a decreased salivary ﬂow rate
may facilitate the formation of salivary stones.2However, we did not ﬁnd an increased prevalence of
salivary stones in patients with Sjögren syndrome.
The relatively high prevalence of Sjögren syndrome
in control patients in the present study (see Table I),
is probably explained by the fact that patients with a
suspicion of Sjögren syndrome are frequently referred
to Oral and Maxillofacial surgeons for further
investigation and subsequently are overrepresented in
the control group.
Two case reports suggested a possible relation be-
tween salivary stone formation and medication. Perrotta
et al.18 described a 57-year-old woman with Parkinson
disease and salivary stones in both the submandibular
gland and the parotid gland and was treated with
levodopa and amantadine. The authors suggested that
the medication may have contributed to sialolith for-
mation in this patient. Another case report19 described a
76-year-old woman with salivary stones in the
submandibular glands and had a medical history of
hypertension, a myocardial infarction 2 years earlier,
and use of methyldopa.
Many types of medications, such as diuretics, an-
tihistamines, antihypertensive drugs, antipsychotic
medications, and antidepressants, decrease the sali-
vary ﬂow rate. The use of these medications could
subsequently facilitate the formation of salivary
stones.9 The use of diuretics in the cohort group of
Huoh and co-workers16 was higher than in the
general population. In the present case control study,
the use of diuretics in patients with salivary stone
formation was comparable with the control group
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Zenk et al.,10 where the use of diuretics by patients
with salivary stones formation was comparable with
that in the general population. Our case control
study also conﬁrms the ﬁnding in the study by Zenk
et al.10 that the use of thyroid medications and
antidiabetes medications by patients with salivary
stone formation is comparable with that by
individuals without a salivary stone.
The use of antibiotics was higher in the group of
patients with salivary stone formation compared with
the control group (see Table II). This may be related to
the fact that salivary stone formation is frequently
associated with sialadenitis.20 In many cases, the
referring dentist or general practitioner may have
prescribed antibiotics as initial treatment.
Huoh et al16 found a higher rate of smoking or
history of smoking in patients with salivary stones
than in the general population, although the difference
did not reach statistical signiﬁcance. In our case
control study, we observed a similar trend, with more
smokers among patients with salivary stone
formation, suggesting that smoking increases the risk
of developing a salivary stone. Tobacco smoking can
cause inﬂammation and the subsequent formation of a
mucus plug and intraglandular concretion, which
ultimately result in the formation of a salivary stone.9,20
The mean age of the patients with salivary stone
formation in the present study is comparable with that
of previous studies.5,6,10,16 The distribution of salivary
stones over the different salivary glands is also in
accordance with previous reports.5,9,18,20,21 In the pre-
sent study, a small male preponderance was observed,
which is in agreement with the study of Zenk et al.10
Older studies found a more extensive male
preponderance.4,5
A potential limitation of the present case control
study is the use of data from medical records, which
had not speciﬁcally been recorded for scientiﬁc pur-
poses. Incompleteness of information in medical history
records is rather common.22 Another potential
limitation is the hospital-based character of the study.
The control patients also had been referred to the de-
partments of Oral Maxillofacial Surgery for speciﬁc
diseases, such as oral malignancies and Sjögren syn-
drome. This means that systemic factors that are asso-
ciated with these oral diseases may have been
overrepresented in the control group thereby obscuring
the potential contribution of certain systemic factors in
the development of salivary stones.
Despite these limitations, the data of the present case
control study indicate that systemic diseases and use of
medication do not play a prominent role in the devel-
opment of salivary stones. This suggests that local
factors, such as anatomic variations of the salivaryducts, an altered biochemical composition of saliva, or
both are probably more important factors in the devel-
opment of salivary stones.23REFERENCES
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